Founders Financial Securities LLC Sells 1,411 Shares of Zoetis Inc. (NYSE:ZTS)

Founders Financial Securities LLC decreased its position in Zoetis Inc. (NYSE:ZTS) by 29.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,310 shares of the company’s stock after selling 1,411 shares during the period. Founders Financial Securities LLC’s holdings in Zoetis were worth $560,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mutual Advisors LLC lifted its stake in shares of Zoetis by 4.0% in the 3rd quarter. Mutual Advisors LLC now owns 3,195 shares of the company’s stock valued at $556,000 after purchasing an additional 122 shares during the period. Fred Alger Management LLC raised its position in shares of Zoetis by 153.8% in the 3rd quarter. Fred Alger Management LLC now owns 11,382 shares of the company’s stock valued at $1,980,000 after acquiring an additional 6,898 shares during the period. SRS Capital Advisors Inc. raised its holdings in Zoetis by 130.6% in the third quarter. SRS Capital Advisors Inc. now owns 4,976 shares of the company’s stock worth $866,000 after purchasing an additional 2,818 shares during the period. Insigneo Advisory Services LLC boosted its position in shares of Zoetis by 65.2% during the third quarter. Insigneo Advisory Services LLC now owns 2,795 shares of the company’s stock worth $486,000 after purchasing an additional 1,103 shares in the last quarter. Finally, AQR Capital Management LLC increased its position in shares of Zoetis by 52.3% in the 3rd quarter. AQR Capital Management LLC now owns 66,328 shares of the company’s stock valued at $11,540,000 after buying an additional 22,779 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on ZTS. Barclays dropped their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 23rd. Piper Sandler reaffirmed an “overweight” rating and issued a $195.00 target price (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Stifel Nicolaus cut their price target on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, April 30th. The Goldman Sachs Group decreased their price objective on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a report on Monday, May 6th. Finally, HSBC decreased their price target on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $211.75.

Zoetis Price Performance

Shares of NYSE ZTS traded down $3.10 during mid-day trading on Friday, reaching $173.36. The company had a trading volume of 4,189,580 shares, compared to its average volume of 2,374,760. The business’s 50-day simple moving average is $168.69 and its 200 day simple moving average is $178.72. The firm has a market cap of $79.10 billion, a price-to-earnings ratio of 33.40, a PEG ratio of 2.69 and a beta of 0.88. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. The firm had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The business’s revenue was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.31 EPS. On average, research analysts predict that Zoetis Inc. will post 5.76 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be paid a $0.432 dividend. The ex-dividend date is Thursday, July 18th. This represents a $1.73 dividend on an annualized basis and a yield of 1.00%. Zoetis’s dividend payout ratio (DPR) is presently 33.33%.

Insider Activity

In other news, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total value of $139,529.91. Following the completion of the transaction, the executive vice president now directly owns 14,800 shares of the company’s stock, valued at $2,237,316. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.